INS and metabolic disease: Compatible with the overlapping elevation of miR-132 in anxiety and metabolic impairments, our enrichment analysis revealed several metabolic disorders, such as non-alcoholic fatty liver disease (NAFLD, FDR = 2.8E−04), inflammatory bowel disease (IBD, FDR = 1.4E−02), and Type II diabetes mellitus (FDR = 8.5E−05), alongside with metabolic-related pathways, such as the Insulin signaling pathway (FDR = 5.3E−09).